First Line Trials


1. Study of Nivolumab (BMS-936558) in Combination With Gemcitabine/Cisplatin, Pemetrexed/Cisplatin, Carboplatin/Paclitaxel, Bevacizumab, Maintenance, Erlotinib, Ipilimumab or as Monotherapy in Subjects With Stage IIIB/IV Non-small cell Lung Cancer (NSCLC) (CheckMate 012) 
 
          ClinicalTrials.gov Identifier:                   NCT01454102         

Active, not recruiting 
 
The study is evaluating the safety and tolerability of Nivolumab as monotherapy among subjects with untreated, asymptomatic brain metastases and no evidence of cerebral edema.

Ontario
Ottawa
Toronto
Hamilton 
 

2. A Phase I/Ib Study of MEK162, a MEK Inhibitor, in Combination With Carboplatin and Pemetrexed in Patients With Non-squamous Carcinoma of the Lung

         ClinicalTrials.gov Identifier:                  NCT02185690        

This study is not yet open for participant recruitment

MEK162 has shown significant inhibition of tumor growth as a single agent in NSCLC xenograft models in mice and human cancer cells in vitro, which have KRAS and/or other mutations. These data suggest that MEK162 may provide a potential benefit in cancer indications harboring these mutations. MEK162 is currently being investigated in phase I clinical testing and has been well tolerated up to an MTD of 45mg BID in cancer patients. 

Alberta
Cross Cancer Institute 
Edmonton, Alberta, T6G1Z2

Ontario
Juravinski Cancer Centre
Hamilton, Ontario, L8V 5C2 
 
The Ottawa Hospital Regional Cancer Centre  
Ottawa, Ontario,  K1G 3Y9
 
Princess Margaret Cancer Centre
Toronto, Ontario,  M5G2M9

3. Randomized, Double-Blind, Multicenter, Study Comparing Veliparib Plus Carboplatin and Paclitaxel Versus Placebo Plus Carboplatin and Paclitaxel in Previously Untreated Advanced or Metastatic Squamous Non-Small Cell Lung Cancer 

       ClinicalTrials.gov Identifier:                 NCT02106546        
 
This study is ongoing, but not recruiting participants. 
 
This is a 2 arm Phase 3 study to evaluate the safety and efficacy of the addition of veliparib plus carboplatin and paclitaxel versus the addition of placebo plus carboplatin and paclitaxel in subjects with advanced or metastatic squamous NSCLC. 

Alberta
Calgary, T2N 4N2
Edmonton, T6G 1Z2

Ontario
Hamilton, L8V 5C2
London, N6A 4L6
Ottawa, K1H 8L6
Toronto, M5G 2M9

Quebec
Levis, G6V 3Z1
Quebec, G1V 4G5

4. Chemotherapy and Radiation Therapy With or Without Metformin Hydrochloride in Treating Patients With Stage III Non-small Cell Lung Cancer

      ClinicalTrials.gov Identifier:               NCT02186847     

This study is ongoing, but not recruiting participants.
 
This randomized phase II trial studies how well chemotherapy and radiation therapy given with or without metformin hydrochloride works in treating patients with stage III non-small cell lung cancer. Drugs used in chemotherapy, such as carboplatin and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Radiation therapy uses high-energy x-rays to kill tumor cells and shrink tumors. Metformin hydrochloride may shrink tumors and keep them from coming back. It is not yet known whether chemotherapy and radiation therapy is more effective when given with or without metformin hydrochloride in treating stage III non-small cell lung cancer. 

Ontario
Juravinski Center  
Hamilton, Ontario,  L8V 5C2
 
5. A Phase III Study of MPDL3280A (Anti-PD-L1) in Combination With Carboplatin + Paclitaxel or Carboplatin + Nab-paclitaxel Compared With Carboplatin + Nab-paclitaxel in Patients With Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC) [IMpower 131]
 
        ClinicalTrials.gov Identifier:                 NCT02367794        

This randomized, open-label study will evaluate the safety and efficacy of Atezolizumab (MPDL3280A) in combination with carboplatin + paclitaxel or carboplatin + nab-paclitaxel compared with treatment with carboplatin + nab-paclitaxel in chemotherapy-naïve patients with Stage IV squamous non-small cell lung cancer (NSCLC).

Ontario
Barrie, Ontario, L4M 6M2
Etobicoke, Ontario, M9V 1R8

Quebec
Montreal
Laval

British Columbia 
Surrey 
 

6. Study Comparing Veliparib Plus Carboplatin and Paclitaxel Versus Investigator's  Choice of Standard Chemotherapy in Subjects Receiving First Cytotoxic Chemotherapy for Metastatic or Advanced Non-Squamous Non-Small Cell Lung Cancer Who Are Current or Former Smokers

        ClinicalTrials.gov Identifier:                 NCT02264990        


This study is ongoing, but not recruiting participants. 

A Randomized, Open-Label, Multicenter, Phase 3 Trial Comparing Veliparib Plus Carboplatin and Paclitaxel Versus Investigator's Choice of Standard Chemotherapy in Subjects Receiving First Cytotoxic Chemotherapy for Metastatic or Advanced Non-Squamous Non-Small Cell Lung Cancer (NSCLC) and Who Are Current or Former Smokers.

Nova Scotia
Halifax

Ontario
London
Windsor 

Quebec
Levis 
 

7. A Phase III Study of MPDL3280A (Anti-PD-L1 Antibody) in Combination With Carboplatin + Paclitaxel With or Without Bevacizumab in Patients With Stage IV Non-squamous Non-small Cell Lung Cancer [IMpower 150]

      ClinicalTrials.gov Identifier:              NCT02366143      

 
This randomized, open-label study will evaluate the safety and efficacy of Atezolizumab (MPDL3280A) in combination with carboplatin and paclitaxel with or without bevacizumab compared with treatment with carboplatin plus (+) paclitaxel and bevacizumab in chemotherapy-naïve patients with Stage IV non-squamous non-small cell lung cancer (NSCLC).

Ontario
Oshawa

8.  An Open-Label, Trial of Nivolumab, or Nivolumab Plus Ipilimumab, or Nivolumab Plus Platinum-doublet Chemotherapy Versus Platinum Doublet Chemotherapy in Subjects With Stage IV Non-Small Cell Lung Cancer (NSCLC) (CheckMate 227)

       ClinicalTrials.gov Identifier:              NCT02477826      


An Open-Label, Randomized Phase 3 Trial of Nivolumab, or Nivolumab Plus Ipilimumab, or Nivolumab Plus Platinum Doublet Chemotherapy Versus Platinum Doublet Chemotherapy in Subjects With Chemotherapy-Naïve Stage IV or Recurrent Non-Small Cell Lung Cancer (NSCLC). 

The purpose of this study is to show that nivolumab, or nivolumab plus ipilimumab, or nivolumab plus platinum-doublet chemotherapy improves progression free survival and/or overall survival compared with chemotherapy in subjects advanced lung cancer.

Alberta
Cross Cancer Institute, Edmonton

Newfoundland
St. John's NL

Ontario
London

Quebec
Montreal
Rimouski 
Trois Rivieres

9. Phase III Open Label First Line Therapy Study of MEDI 4736 With or Without Tremelimumab Versus SOC in Non Small-Cell Lung Cancer (NSCLC). (MYSTIC)

          ClinicalTrials.gov Identifier:                    NCT02453282        

This study is ongoing, but not recruiting participants. 
 
This is a randomized, open-label, multi-center, global, Phase III study to determine the efficacy and safety of MEDI4736 + tremelimumab combination therapy and MEDI4736 monotherapy versus platinum-based SoC chemotherapy in the first-line treatment of patients with epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) wild-type advanced or metastatic NSCLC.

Ontario 
Kingston
Oshawa
Newmarket
Sudbury 
Sault Ste Marie
St. Catharines 

Saskatchewan
Regina
Saskatoon

10. A Study of Ramucirumab (LY3009806) in Combination With Erlotinib in Participants With EGFR Mutation-Positive Metastatic NSCLC (RELAY)

         ClinicalTrials.gov Identifier:                    NCT02411448          
 
A Multicenter, Randomized, Double-Blind Study of Erlotinib in Combination With Ramucirumab or Placebo in Previously Untreated Patients With EGFR Mutation-Positive Metastatic Non-Small Cell Lung Cancer.

Ontario
London

Quebec
Montreal

Alberta
Edmonton

11. Avelumab in First-line Non-Small Cell Lung Cancer (JAVELIN Lung 100)

           ClinicalTrials.gov Identifier:                    NCT02576574        

The purpose of this study is to demonstrate superiority with regard to progression free survival (PFS) based on an Independent Review Committee (IRC) assessment of avelumab versus platinum-based doublet in non-small cell lung cancer (NSCLC) subjects with Programmed death ligand 1+ (PD-L1+) tumours.

Nova Scotia
Capital District Health Authority
Halifax,  B3H 1V8

12. Nivolumab Plus Ipilimumab to Treat First Line Stage IV Non-Small Cell Lung Cancer (CheckMate568)

 
            ClinicalTrials.gov Identifer:                        NCT02659059         
 

The purpose of this study is to determine the objective response rate (ORR) in PD-L1+ stage IV NSCLC subjects treated with nivolumab in combination with ipilimumab as first line therapy.

Ontario 
Kingston Regional Cancer Centre  
Kingston,  K7L 2V7
 
Sault Area Hospital  
Sault Ste Marie, Ontario,  P6B 0A8

Quebec
CSSS De St-Jerome
St-Jerome,  J7Z 5T3


13. Trial of BMS-986012 in Combination With Platinum and Etoposide

         ClinicalTrials.gov Identifier:                   NCT02815592          

The purpose of this this study is to administer BMS-986012 in Combination with Platinum and Etoposide as First-line Therapy in Extensive Small Cell Lung Cancer.

Alberta
Local Institution 
Edmonton, , T6G 1Z2
Contact: Site 0005    

Ontario 
Local Institution
Ottawa,  K1H 8L6
Contact: Site 0008     
    
Local Institution
Toronto,  M5G 2M9
Contact: Site 0006      
  

14. A Phase 1b Study of MEDI4736 in Combination With Tremelimumab in Subjects With Advanced Non-small Cell Lung Cancer (D4190C00006)

         ClinicalTrials.gov Identifier:                   NCT02000947         

The purpose of this study is to determine if MEDI4736 will be adequately tolerated in combination with tremelimumab in subjects with advanced non-small cell lung cancer (NSCLC).

Alberta
Edmonton 
Ontario 
Toronto 
 

15. A Study of Atezolizumab in Combination With Carboplatin or Cisplatin + Pemetrexed Compared With Carboplatin or Cisplatin + Pemetrexed in Participants Who Are Chemotherapy-Naive and Have Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC) (IMpower 132)

        ClinicalTrials.gov Identifier:                 NCT02657434        

A Phase III, Open-Label, Randomized Study of Atezolizumab (MPDL3280A, Anti-Pd-L1 Antibody) in Combination With Carboplatin or Cisplatin + Pemetrexed Compared With Carboplatin or Cisplatin + Pemetrexed in Patients Who Are Chemotherapy-Naive and Have Stage IV Non-Squamous Non-Small Cell Lung Cancer.

Alberta
Edmonton

Ontario
Oshawa
 

16. A Study to Evaluate Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer(NSCLC) (B-FAST)

         ClinicalTrials.gov Identifier:                    NCT03178552         

This is a phase 2/3, global, multicenter, open-label, multi-cohort study designed to evaluate the safety and efficacy of targeted therapies or immunotherapy as single agents or in combination in participants with unresectable, advanced or metastatic NSCLC determined to harbor oncogenic somatic mutations or positive by tumor mutational burden (TMB) assay as identified by two blood-based next-generation sequencing (NGS) circulating tumor DNA (ctDNA) assays.

Alberta
Cross Cancer Institute, Edmonton

Ontario 
Royal Victoria Regional Health Centre; c/o Oncology Clinical Trials       Recruiting
Barrie, Ontario, Canada, L4M 6M2
 
William Osler Health System Brampton Civic Hospital       Recruiting
Brampton, Ontario, Canada, L6R 3J7
 
London Health Sciences Centre · Victoria Hospital; Department of Medicine       Recruiting
London, Ontario, Canada, N6A 5W9
 
Lakeridge Health Center; R. S. MacLaughlin Durham Regional Cancer Center       Recruiting
Oshawa, Ontario, Canada, L1G 2B9
 
Sunnybrook Health Sciences Centre        Recruiting
Toronto, Ontario, Canada, M4N 3M5
 
University Health Network; Princess Margaret Hospital; Medical Oncology Dept       Recruiting
Toronto, Ontario, Canada, M5G 2M9

Quebec
Jewish General Hospital; Sir Mortimer B. Davis                                                           Recruiting
Montreal, Quebec, Canada, H2W 1S6
 
IUCPQ (Hôpital Laval)                                                                                                  Recruiting
Quebec City, Quebec, Canada, G1V 4G5

Saskatchewan 
Saskatoon Cancer Agency                                                                                          Recruiting
Saskatoon, Saskatchewan, Canada, SK S7N 4H
 
Manitoba 
CancerCare Manitoba; Department of Medical Oncology                                         Recruiting
Winnipeg, Manitoba, Canada, R3E 0V9

17. A Study of Atezolizumab Compared With Chemotherapy in Treatment Naïve Participants With Locally Advanced or Recurrent or Metastatic Non-Small Cell Lung Cancer Who Are Deemed Unsuitable For Platinum-Containing Therapy (IPSOS)

        ClinicalTrials.gov Identifier:                  NCT03191786        

This Phase III, global, multicenter, open-label, randomized, controlled study will evaluate the efficacy and safety of atezolizumab (an anti-programmed death-ligand 1 [anti-PD-L1] antibody) compared with a single agent chemotherapy regimen by investigator choice (vinorelbine or gemcitabine) in treatment-naïve participants with locally advanced or metastatic non-small cell lung cancer (NSCLC) who are deemed unsuitable for any platinum-doublet chemotherapy due to poor performance status (Eastern Cooperative Oncology Group [ECOG] performance status of 2-3).
 
New Brunswick
Regional health authority A vitalite health network Active, not recruiting
Moncton, New Brunswick, Canada, E1C 8X3
 
Ontario
Ottawa Hospital Research Institute Active, not recruiting
Ottawa, Ontario, Canada, K1Y 4E9
 
Sault Area Hospitals Terminated
Sault Ste Marie, Ontario, Canada, P6A 2C4
 
Princess Margaret Cancer Center Active, not recruiting
Toronto, Ontario, Canada, M5G 1Z5
 
Quebec
McGill University; Sir Mortimer B Davis Jewish General Hospital; Oncology       Active, not recruiting
Montreal, Quebec, Canada, H3T 1E2

18. Study of Pemetrexed + Platinum Chemotherapy With or Without Pembrolizumab (MK-3475) in Adults With Tyrosine Kinase Inhibitor- (TKI)-Resistant Epidermal Growth Factor Receptor- (EGFR)-Mutated Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-789/KEYNOTE-789)​

        ClinicalTrials.gov Identifier:                     NCT03515837          
 
The purpose of this study is to evaluate the efficacy and safety of pemetrexed plus platinum chemotherapy (carboplatin or cisplatin) with or without pembrolizumab (MK-3475; KEYTRUDA®) in the treatment of adults with the following types of tyrosine kinase inhibitor (TKI)-resistant, epidermal growth factor receptor (EGFR)-mutated, metastatic non-squamous non-small cell lung cancer (NSCLC) tumors: 1) TKI-failures (including osimertinib [TAGRISSO®] failure) with T790M-negative mutation tumors, 2) T790M-positive mutation tumors with prior exposure to osimertinib, and 3) first-line osimertinib failure regardless of T790M mutation status.

The primary study hypotheses are that the combination of pembrolizumab plus chemotherapy has superior efficacy compared to saline placebo plus chemotherapy in terms of: 1) Progression-free Survival (PFS) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) based on blinded independent central review, and 2) Overall Survival (OS). This study will be considered to have met its success criteria if the combination of pembrolizumab plus chemotherapy is superior to saline placebo plus chemotherapy in terms of PFS or OS.
 
Ontario
William Osler Health System (Site 0100)          Recruiting
Brampton, Ontario, Canada, L6R 3J7
Contact: Study Coordinator, 905-494-2120 x 57263      
 
Sunnybrook Health Sciences, Odette Cancer Centre (Site 0102)          Recruiting
Toronto, Ontario, Canada, M4N 3M5
Contact: Study Coordinator, 416-480-5000 x 7955   
  
Princess Margaret Cancer Centre (Site 0104)          Recruiting
Toronto, Ontario, Canada, M5G 2M9
Contact: Study Coordinator, 416-946-2913   
  
Quebec
Jewish General Hospital (Site 0105)          Recruiting
Montreal, Quebec, Canada, H3T 1E2
Contact: Study Coordinator, +514-340-8222 x 23674      

19. Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (MK-7902/E7080) in Adults With Programmed Cell Death-Ligand 1 (PD-L1)-Positive Treatment-naïve Non-small Cell Lung Cancer (NSCLC)(MK-7902-007/E7080-G000-314/LEAP-007)

         ClinicalTrials.gov Identifier:                    NCT03829332          

The purpose of this study is to assess the safety and efficacy of pembrolizumab (MK-3475) combined with lenvatinib (MK-7902/E7080) compared to pembrolizumab alone (with placebo for lenvatinib) in treatment-naïve adults with no prior systemic therapy for their metastatic non-small cell lung cancer (NSCLC) whose tumors have a programmed cell death-ligand 1 (PD-L1) Tumor Proportion Score (TPS) greater than or equal to 1%.
The primary study hypotheses are that: 1) The combination of pembrolizumab and lenvatinib is superior to pembrolizumab alone as assessed by Progression-free Survival (PFS) per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1), and 2) The combination of pembrolizumab and lenvatinib is superior to pembrolizumab alone as assessed by Overall Survival (OS).
 
Alberta
Cross Cancer Institute (Site 0400)               Recruiting
Edmonton, Alberta, Canada, T6G 1Z2
Contact: Study Coordinator, 780-432-8762      
 
Ontario
William Osler Health System (Brampton Civic Hospital) (Site 0402)              Recruiting
Brampton, Ontario, Canada, L6R 3J7
Contact: Study Coordinator, 905-494-2120 x 58389   
  
Windsor Regional Cancer Program (Site 0404)              Recruiting
Windsor, Ontario, Canada, N8W 2X3
Contact: Study Coordinator, 519-253-5253      
 

20. A Study of Biomarker-Directed, Pembrolizumab (MK-3475) Based Combination Therapy for Advanced Non-Small Cell Lung Cancer (MK-3475-495/KEYNOTE-495)

         ClinicalTrials.gov Identifier:                    NCT03516981        

This study will investigate the utility of biomarker-based triage for study participants with advanced non-small cell lung cancer (NSCLC) without prior systemic therapy. Study participants within groups defined by a biomarker-based classifier (gene expression profile [GEP] and tumor mutational burden [TMB]) will be randomized to receive pembrolizumab in combination with MK-1308, MK-4280, or lenvatinib. The primary hypotheses are as follows: In participants receiving pembrolizumab in combination with either MK-1308, MK-4280, or lenvatinib, the Objective Response Rate (ORR) will be 1) greater than 5% among participants with low GEP and low TMB, 2) greater than 20% among participants with low GEP and high TMB, 3) greater than 20% among participants with high GEP and low TMB, and 4) greater than 45% among participants with high GEP and high TMB.
 
Ontario
Sunnybrook Health Science Centre (Site 0304)             Recruiting
Toronto, Ontario, Canada, M4N 3M5
Contact: Study Coordinator, 416-480-5000 x 7955      
 
Quebec
Jewish General Hospital ( Site 0307)             Recruiting
Montreal, Quebec, Canada, H3T 1E2
Contact: Study Coordinator, 514-340-8222 x 23674      

21. A Study of Nivolumab and Ipilimumab Combined With Chemotherapy Compared to Chemotherapy Alone in First Line NSCLC (CheckMate 9LA)

          ClinicalTrials.gov Identifier:                   NCT03215706         

The purpose of this study is to determine whether Nivolumab, Ipilimumab combined with chemotherapy is more effective than chemotherapy by itself when treating stage IV NSCLC as the first treatment given for the disease.
 
Quebec
Local Institution         Active, not recruiting
Montreal, Quebec, Canada, H1T 2M4
 
Jewish General Hospital         Active, not recruiting
Montreal, Quebec, Canada, H3T 1E2
 
Mcgill University Health Center - Royal Victoria Hospital         Active, not recruiting
Montreal, Quebec, Canada, H4A 3J1
 
Local Institution         Withdrawn
Montreal, Quebec, Canada, H4J 1C5
 
CISSS du Bas-Saint-Laurent Hopital Regional de Rimouski         Active, not recruiting
Rimouski, Quebec, Canada, G5L 5T1

22. Clinical Study of Oral cMET Inhibitor INC280 in Adult Patients With EGFR Wild-type Advanced Non-small Cell Lung Cancer

         ClinicalTrials.gov Identifier                  NCT02414139        

A phase II study to evaluate antitumor activity of oral cMET inhibitor INC280 in adult patients with EGFR wild-type, advanced non-small cell lung cancer (NSCLC) as measured by overall response rate (ORR). The study will also evaluate safety and pharmacokinetics of INC280.
 
Nova Scotia
Novartis Investigative Site                               Recruiting
Halifax, Nova Scotia, Canada, B3H 1V7
Ontario
Novartis Investigative Site                               Recruiting
Ottawa, Ontario, Canada, K1H 8L6
 

23. Study of Pembrolizumab Given With Ipilimumab or Placebo in Participants With Untreated Metastatic Non-small Cell Lung Cancer (MK-3475-598/KEYNOTE-598)

         ClinicalTrials.gov Identifier:                    NCT03302234         

The purpose of this study is to determine the efficacy of pembrolizumab given in combination with either ipilimumab or placebo as first-line treatment in participants with metastatic non-small cell lung cancer (NSCLC). The primary hypothesis of this study is that overall survival (OS) and/or progression-free survival (PFS) is prolonged in participants who receive pembrolizumab and ipilimumab compared to those who receive pembrolizumab and placebo.
 
Alberta
Tom Baker Cancer Centre (Site 0119)           Recruiting
Calgary, Alberta, Canada, T2N 4N2
Contact: Study Coordinator, 403-521-3347
     
Manitoba
CancerCare Manitoba (Site 0106)            Recruiting
Winnipeg, Manitoba, Canada, R3E 0V9
Contact: Study Coordinator, 204-787-8776      
 
Quebec
CIUSSS du Saguenay-Lac-St-Jean (Site 0115)           Recruiting
Chicoutimi, Quebec, Canada, G7H 5H6
Contact: Study Coordinator, 418-541-1234 x 2840
     
CISSS de la Monteregie-Centre (Site 0100)           Recruiting
Greenfield Park, Quebec, Canada, J4V 2H1
Contact: Study Coordinator, 450-466-5000 x 3226  
    
CISSS-CA Hotel-Dieu de Levis (Site 0108)            Recruiting
Levis, Quebec, Canada, G6V 3Z1
Contact: Study Coordinator, 418-835-7121 x 3048   
  
CIUSSS Ouest de l'Ile - St-Mary's Hospital (Site 0107)           Recruiting
Montreal, Quebec, Canada, H3T 1M5
Contact: Study Coordinator, 514-345-3511 x 3981  
    
St-Jerome Medical Research Inc (Site 0113)           Recruiting
St-Jerome, Quebec, Canada, J7Z 5T3
Contact: Study Coordinator,  450431102042      

24. Study of Efficacy and Safety of Pembrolizumab Plus Platinum-based Doublet Chemotherapy With or Without Canakinumab in Previously Untreated Locally Advanced or Metastatic Non-squamous and Squamous NSCLC Subjects (CANOPY-1)

         ClinicalTrials.gov Identifier:                 NCT03631199       

This is a phase III study of pembrolizumab plus platinum-based doublet chemotherapy with or without canakinumab in previously untreated locally advanced or metastatic non-squamous and squamous NSCLC subjects.

The study will assess primarily the safety and tolerability (safety run-in part) of pembrolizumab plus platinum-based doublet chemotherapy with canakinumab and then the efficacy (double-blind, randomized, placebo controlled part) of pembrolizumab plus platinum-based doublet chemotherapy with or without canakinumab.

Ontario 
Novartis Investigative Site                                 Recruiting
Toronto, Ontario, Canada, M5G 1Z6

25. A Study of Tislelizumab (BGB-A317) Plus Chemoradiotherapy Followed by Tislelizumab Monotherapy in Newly Diagnosed, Stage III Subjects With Locally Advanced, Unresectable Non-small Cell Lung Cancer (RATIONALE001)

 
            ClinicalTrials.gov Identifier:                         NCT03052608              

This is a Phase 3, randomized, double-blind, placebo-controlled multicenter global study designed to compare the efficacy and safety of tislelizumab in combination with concurrent chemoradiotherapy (cCRT) followed by tislelizumab monotherapy versus cCRT alone, and tislelizumab given sequentially after cCRT versus cCRT alone, in newly diagnosed stage III subjects with locally advanced, unresectable non-small cell lung cancer (NSCLC). The primary endpoint is centrally-assessed PFS in the intent-to-treat (ITT) population. Newly diagnosed stage III subjects with histologically confirmed, locally advanced, unresectable NSCLC are eligible.

Quebec
Jewish General Hospital                                            Not yet recruiting
Montreal, Quebec, Canada, H3T 1E2

26. A Study Of Lorlatinib Versus Crizotinib In First Line Treatment Of Patients With ALK-Positive NSCLC

        ClinicalTrials.gov Identifier:                  NCT03052608         

A phase 3 study to demonstrate whether lorlatinib given as monotherapy is superior to crizotinib alone in prolonging the progression-free survival in advanced ALK-positive NSCLC patients who are treatment naïve and to compare lorlatinib to crizotinib with respect to overall survival in the same population.

Ontario
Princess Margaret Cancer Centre                               Recruiting
Toronto, Ontario, Canada, M5G 2M9

Quebec
McGill University Health Centre                                 Recruiting
Montreal, Quebec, Canada, H4A 3J1